Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-165 vs Bevacizumab with FOLFIRI in Metastatic Colorectal Cancer
NCT03368859Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of dilpacimab in colorectal cancer (CRC), sponsored by AbbVie Inc.. Started Mar 2018; status: terminated.
02
Drugs
dilpacimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03368859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03368859.